Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers-Reference-Cited by-同舟云学术

Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers

Published:2023-08-01 Issue:8 Volume:9 Page:1144
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Richters Anke¹,Yildirim Hilin¹,Booth Christopher M.²,Vera Badillo Francisco E.³,Kiemeney Lambertus A. L. M.⁴,Aben Katja K. H.¹

Affiliation:

1. Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands

2. Division of Cancer Care and Epidemiology, Queen’s University Cancer Research Institute, Kingston, Ontario, Canada

3. Department of Oncology, Queen’s University, Kingston, Ontario, Canada

4. Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands

Abstract

This systematic review investigates how often and to what extent primary end points are changed and reported in immune checkpoint inhibitor clinical trials.

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2805960/jamaoncology_richters_2023_ld_230008_1691789066.81364.pdf

Reference6 articles.

1. Immune checkpoint inhibitors.;West;JAMA Oncol,2015

2. Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers.;Parikh;JAMA Oncol,2021

3. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials.;Schulz;Trials,2010

4. Clinical trial registration: a statement from the International Committee of Medical Journal Editors.;Deangelis;Arch Dermatol,2005

5. Comparison of registered and published primary outcomes in randomized controlled trials.;Mathieu;JAMA,2009